For the Inventor, By the Inventor

Enter assignee name

Thousand Oaks, CA, United States of America

Immunex Corporation

USPTO Granted Patents = 451

CIPO Patents = 13

EPO Patents = 25

Trademarks = 12

Forward Citations = 9,602

Loading Chart...

Loading Chart...

193 inventors (with patents filed for the assignee):

John Ernest Sims (60 out of 66 patents)

Dirk M Anderson (50 out of 53 patents)

David J Cosman (41 out of 43 patents)

4. Douglas Pat Cerretti (38 out of 45 patents)

5. Raymond G Goodwin (34 out of 39 patents)

6. Richard Jeffrey Armitage (33 out of 39 patents)

7. Carl J March (32 out of 32 patents)

8. Melanie K Spriggs (32 out of 33 patents)

9. M Patricia Beckmann (32 out of 35 patents)

10. William Christian Fanslow, Iii (28 out of 36 patents)

11. Stewart D Lyman (25 out of 28 patents)

12. Craig A Smith (24 out of 32 patents)

13. Bruce A Mosley (19 out of 19 patents)

14. Peter Robert Baum (19 out of 31 patents)

15. Steven R Wiley (18 out of 23 patents)

Core Competencies:

Anti-Human VISTA Antibodies

Tumor Necrosis Factor Receptor

Interleukin-4 Receptor Antibodies

TSLP Activity Inhibition

RANK Ligand Polypeptides

Inflammatory Disorders Treatment

Leukocyte Immunoglobulin-Like Receptors

Blocking Antibodies to Human RANKL

C-Type Lectin Polypeptides

Modified Human Thymic Stromal Lymphopoietin

VISTA/VSIG8 Agonists

Osteoclast Activity Inhibition

451 patents: Sort by Forward Citations

1. 12139532 - Anti-human vista antibodies and use thereof (2024-11-12),

2. 11649283 - Anti-human vista antibodies and use thereof (2023-05-16),

3. 11603403 - Anti-human vista antibodies and use thereof (2023-03-14),

4. 11603402 - Anti-human vista antibodies and use thereof (2023-03-14),

5. 11596689 - Methods of immunosuppression comprising administering an anti-CD154 antibody (2023-03-07),

6. 11525000 - Anti-human VISTA antibodies and use thereof (2022-12-13),

7. 11104714 - Compositions comprising a P75 tumor necrosis factor receptor/Ig fusion protein (2021-08-31),

8. 10874738 - Anti-CD154 antibody having improved binding, functional and safety characteristics (2020-12-29),

9. 10370455 - Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists (2019-08-06),

10. 9587026 - Anti-interleukin-4 receptor antibodies (2017-03-07),

11. 9518111 - Compositions comprising a p75 tumor necrosis factor receptor/Ig fusion protein (2016-12-13),

12. 9346870 - Antibodies that inhibit TSLP activity (2016-05-24),

13. 9045558 - Nucleic acids encoding modified human thymic stromal lymphopoietin (2015-06-02),

14. 8828947 - Polypeptide formulation (2014-09-09),

15. 8722631 - Soluble tumor necrosis factor receptor treatment of medical disorders (2014-05-13),

Immunex Corporation is a biotechnology company focused on researching and developing innovative therapies for serious medical conditions. With a primary emphasis on autoimmune diseases, the company is committed to advancing scientific understanding and improving patient care. Visit their website for more information.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

451 Patents

#2 in Thousand Oaks, CA

#236 in California

#1,022 in US

#2,047 in the World

Thousand Oaks, CA, United States of America

Immunex Corporation

Forward Citations = 9,602

193 inventors:

John Ernest Sims (60 out of 66 patents)

Dirk M Anderson (50 out of 53 patents)

David J Cosman (41 out of 43 patents)

4. Douglas Pat Cerretti (38 out of 45 patents)

5. Raymond G Goodwin (34 out of 39 patents)

Please report any incorrect information to support@idiyas.com

Loading…